Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1922623 | 0.92 | POLB (0.40) | CYP2C19SMN1; SMN2ACEPOLB | |
| SCHEMBL1010635 | 0.92 | POLB (0.40) | CYP2C19SMN1; SMN2ACEPOLB | |
| SCHEMBL1009458 | 0.90 | ACE (0.42) | CYP2C19SMN1; SMN2ACEPOLBCYP1A2 | |
| SCHEMBL1923117 | 0.90 | ACE (0.42) | CYP2C19SMN1; SMN2ACEPOLBCYP1A2 | |
| SCHEMBL1010960 | 0.86 | ACE (0.41) | CYP2C19ACEPOLBCYP1A2CYP2C9 | |
| SCHEMBL1011805 | 0.84 | COPS5 (0.36) | SMN1; SMN2CYP2C9 | |
| SCHEMBL1012425 | 0.84 | TBXA2R (0.41) | SMN1; SMN2CYP2C9 | |
| SCHEMBL3443079 | 0.81 | PTGDR2 (0.47) | CYP2C19SMN1; SMN2POLBCYP1A2CYP2C9 | |
| SCHEMBL3443075 | 0.81 | PTGDR2 (0.47) | CYP2C19SMN1; SMN2POLBCYP1A2CYP2C9 | |
| SCHEMBL1066125 | 0.79 | POLB (0.42) | SMN1; SMN2ACEPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960393-B2 | Pyrimidine derivatives useful for the treatment of diseases mediated by CRTH2 | ACTIMIS PHARMACEUTICALS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| EP-1633726-B1 | PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES MEDIATED BY CRTH2 | ACTIMIS PHARMACEUTICALS INC (US) | 2011-01-05 | — | — | EP | disclosed |